New drug SKB264 takes on advanced breast cancer in major trial

NCT ID NCT07071337

Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy for people with a common type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy. About 430 participants will be randomly assigned to receive either SKB264 or one of several chemotherapy drugs. The main goal is to see if SKB264 can delay cancer growth better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB264 (a drug given intravenously)
What this could lead to: If successful, SKB264 could offer a new treatment option for people with HR+/HER2- breast cancer that has stopped responding to hormone therapy.
What could go wrong: This is a phase 3 trial, but it is still experimental. SKB264 may not prove better than existing chemotherapies, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The Fifth Medical Center of the Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100039, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.